Back to Search
Start Over
A phase 2 trial of consolidation pembrolizumab following concurrent chemoradiation for patients with unresectable stage III non-small cell lung cancer: Hoosier Cancer Research Network LUN 14-179
- Source :
- CancerReferences. 126(19)
- Publication Year :
- 2020
-
Abstract
- BACKGROUND Five-year overall survival (OS) for patients with unresectable stage III non-small cell lung cancer (NSCLC) is poor. Until recently, a standard of care was concurrent chemoradiation alone. Patients with metastatic NSCLC treated with anti-programmed death 1 antibodies have demonstrated improved OS. This trial evaluated pembrolizumab as consolidation therapy after concurrent chemoradiation in patients with unresectable stage III disease. METHODS Patients with unresectable stage III NSCLC received concurrent chemoradiation with cisplatin and etoposide, cisplatin and pemetrexed, or carboplatin and paclitaxel and 59.4 to 66.6 Gy of radiation. Patients with nonprogression of disease were enrolled and received pembrolizumab (200 mg intravenously every 3 weeks for up to 12 months). The primary endpoint was the time to metastatic disease or death (TMDD). Secondary endpoints included progression-free survival (PFS) and OS. RESULTS The median follow-up for 93 patients (92 for efficacy) was 32.2 months (range, 1.2-46.6 months). The median TMDD was 30.7 months (95% confidence interval [CI], 18.7 months to not reached), which was significantly longer than the historical control of 12 months (P
- Subjects :
- Cancer Research
medicine.medical_specialty
Lung Neoplasms
Programmed Cell Death 1 Receptor
Pembrolizumab
Antibodies, Monoclonal, Humanized
Gastroenterology
03 medical and health sciences
chemistry.chemical_compound
0302 clinical medicine
Internal medicine
Carcinoma, Non-Small-Cell Lung
medicine
Clinical endpoint
Humans
030212 general & internal medicine
Etoposide
Pneumonitis
Aged
Neoplasm Staging
Cisplatin
Aged, 80 and over
business.industry
Chemoradiotherapy
Middle Aged
medicine.disease
Carboplatin
Confidence interval
Pemetrexed
Oncology
chemistry
030220 oncology & carcinogenesis
business
medicine.drug
Subjects
Details
- ISSN :
- 10970142
- Volume :
- 126
- Issue :
- 19
- Database :
- OpenAIRE
- Journal :
- CancerReferences
- Accession number :
- edsair.doi.dedup.....70b7cd82bb0ca5ddc5446872bdca4e8d